Asthma
Conditions
Brief summary
The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.
Interventions
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent, * asthma, * previously treated with glucocorticosteroids and B2-agonist
Exclusion criteria
* History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilities | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of days patients or assistant persons are absent from work due to patient's asthma | — |
| Number of exacerbations and treatment failures | — |
Countries
Sweden
Outcome results
None listed